Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Publication Of Preclinical Proof-Of-Principle Of CPP-115 Efficacy in Suppressing Infantile Spasms In Epilepsia
11/18/2013 8:57:49 AM
CORAL GABLES, Fla., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, today announced that the journal Epilepsia has accepted for publication an original research paper that demonstrates proof of concept of CPP-115 suppressing infantile spasms (IS) in a pre-clinical study. CPP-115 is Catalyst's next-generation GABA aminotransferase inhibitor being developed for the treatment of IS. Catalyst also announced plans to initiate a Phase I multiple-dose ascending study in the first half of 2014 to evaluate the safety and tolerability of multiple ascending oral doses of CPP-115.
Help employers find you! Check out all the jobs and post your resume.
comments powered by